SecBot SecBot

DARE

Dare Bioscience, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001401914 Biotech & Drug Discovery
$0.6432 −0.00 (−0.43%)
Oct 26 4:00 PM ET · prev $0.6460
Market cap
$12.8M
Nano cap
Median target
$8.00
+1144% · range $5.00–12.00
Next earnings
Nov 11
in 16 days · EPS est. −$0.14
1 year
−68.3%
from $2.03 · Oct 27
30 days
−14.2%
from $0.7500
52-week range
$0.6432–3.27
at the low
Avg volume 20D
157.9K
Sep 29 spike 644.4K
Short interest
922.0K
≈4.7% of shares · +7.3%
Days to cover
3.1
at average volume
Insider net
$0
no open-market trades · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
20
analyzed by SecBot
SecBot read BEARISH 8 reports · 90 days
Balance 4 bearish · 0 bullish · 1 mixed · 3 neutral oldest → newest, height = score
Avg score ·High conf. 5/8 ·Next Earnings date, Nov 11, 2026
Strongest BEARISH Dare Bioscience is holding a special meeting on November 10, 2026 to seek stockholder approval for the…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • InstitutionsBULLISH

    Q2 2026: 7 added (0 new), 1 trimmed or exited.

  • EstimatesRISING

    Current-quarter EPS estimate −$0.160 → −$0.140 over 90 days.

  • Short sellersSTEADY

    Short interest +7.3% to 922.0K shares. 3.1 days to cover, ≈4.7% of shares.

  • TrendDOWNTREND

    15% below its 50-day average. New closing low $0.6432 on Oct 26.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
VANGUARD CAPITAL MANAGEMENT LLCADD640,877$1.4M
US BANCORP \DE\ADD120,920$255.1K
VANGUARD FIDUCIARY TRUST COADD91,269$192.6K
BlackRock, Inc.DOUBLED64,248$135.6K
STATE STREET CORPDOUBLED47,415$100.0K
NORTHERN TRUST CORPDOUBLED34,209$72.2K
PRICE T ROWE ASSOCIATES INC /MD/ADD13,318$29.0K
UBS Group AGNEAR_EXIT6,810$14.4K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action Dec 2025
12-month targets · 3 analysts

Price is below the lowest target. Median implies +1144%.Targets as of Oct 26, 2026.

Recent actions
DateFirmActionRating
Dec 2, 2025HC Wainwright & Co.
REITERATE
REITERATEBuy
Sep 4, 2025Maxim Group
UPGRADE
UPGRADEBuy
Apr 1, 2025HC Wainwright & Co.
REITERATE
REITERATEBuy
Dec 17, 2024HC Wainwright & Co.
REITERATE
REITERATEBuy
Nov 15, 2024HC Wainwright & Co.
REITERATE
REITERATEBuy
Oct 24, 2024HC Wainwright & Co.
REITERATE
REITERATEBuy

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
Jun 30, 2026
Kelley Susan L.
Director
AWARD23,696 sh
Jun 30, 2026
Matz Gregory W
Director
AWARD30,805 sh
Jun 30, 2026
Steele Robin Joan
Director
AWARD26,540 sh
Jun 30, 2026
Grossman Jessica D.
Director
AWARD26,066 sh
Jun 30, 2026
RASTETTER WILLIAM H
Director
AWARD38,862 sh
Jun 11, 2026
Grossman Jessica D.
Director
AWARD10,000 sh
Jun 11, 2026
Matz Gregory W
Director
AWARD10,000 sh
Jun 11, 2026
Steele Robin Joan
Director
AWARD10,000 sh

Earnings setup

Estimates
Nov 11
reports in 16 days
−$0.14
EPS estimate, this quarter
+12%
estimate change, 90 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.14-$0.27–$0.10+12.5%$2.0M
Next Q-$0.23-$0.30–-$0.16+15.7%$359.3K
Current FY-$0.77-$0.97–-$0.43+18.3%$2.7M
Next FY-$0.41-$0.52–-$0.31+18.6%$8.9M

Short side

FINRA· Sep 30, 2026
922,037
shares short
+7.3%
vs prior settlement
3.1
days to cover
≈4.7%
of shares outstanding
Trading halts
Aug 14, 2026Volatility PauseResumed
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 26, 2026 Other
🔒 Fresh data, subscribers only
Oct 6, 2026 SEC
Dare Bioscience is holding a special meeting on November 10, 2026 to seek stockholder approval for the potential…
DEF 14A — Impact 6/10
Oct 1, 2026 SEC
Dare Bioscience filed an 8-K on October 1, 2026, to furnish a corporate investor presentation (Exhibit 99.1) under…
8-K — Impact 2/10
Sep 9, 2026 SEC
Dare Bioscience filed an 8-K on September 9, 2026, to furnish a corporate investor presentation (Exhibit 99.1) under…
8-K — Impact 2/10
Jun 30, 2026 Insider
Kelley Susan L. was granted 23,696 shares
Director
Jun 30, 2026 Insider
Matz Gregory W was granted 30,805 shares
Director
Jun 30, 2026 Insider
Steele Robin Joan was granted 26,540 shares
Director
Jun 30, 2026 Inst.
VANGUARD CAPITAL MANAGEMENT LLC — ADD
640,877 shares ($1.4M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 11, 2026
Earnings date
DARE Q3 2026 Earnings Scheduled — 2026-11-11
Recent
Oct 26, 2026
Press release
🔒 Fresh data, subscribers only
Oct 19, 2026
Press release
Daré Bioscience Sponsors HERmedicine Educational Program for Clinicians on Managing Menopause After Breast Cancer
Premier sponsorship of the HERmedicine and OncoMenopause Consortium® program underscores Daré Bioscience's commitment to addressing unmet women’s…
Oct 13, 2026
Press release
Daré Bioscience Launches “CEO Corner” Video Series to Highlight the Company’s Pipeline of Women’s Health Innovations, Corporate Strategy and Opportunities
New video series featuring Founder, President and CEO Sabrina Martucci Johnson will provide investors with insights into Daré Bioscience’s growing...
Sep 28, 2026
Press release
Dare Bioscience Announces New U.S. Patent Strengthening DARE-HPV Program as a Potential First FDA-Approved Pharmacologic Treatment for HPV Infection
New U.S. patent expands intellectual property foundation for DARE-HPV, a potential first-in-category treatment targeting persistent high-risk HPV…
Sep 11, 2026
Company news
Daré Bioscience Presentation for H.C. Wainwright 28th Annual Global Investment Conference Now Available On-Demand
View the video webcast here

SecBot reports

20 filings · 3 press releases · 0 bullish · 6 bearish · 1 mixed · 13 neutral
All DARE filing & press-release reports (23)